Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanjia Lin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biometrics|May 13, 2009
Association models for clustered data with binary and continuous responsesLanjia Lin, Dipankar Bandyopadhyay, Stuart R Lipsitz, et al.
Journal of Hepatology|July 6, 2015
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis BHenry Lik-Yuen Chan, Magdy Elkhashab, Huy Trinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.
Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biometrics|May 13, 2009
Association models for clustered data with binary and continuous responsesLanjia Lin, Dipankar Bandyopadhyay, Stuart R Lipsitz, et al.
Journal of Hepatology|July 6, 2015
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis BHenry Lik-Yuen Chan, Magdy Elkhashab, Huy Trinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.
Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.
Pageof 2